NCT05991908View on ClinicalTrials.gov

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

PHASE3RecruitingINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

June 30, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Fludarabine, busulfan and melphalan

FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2

DRUG

Fludarabine and Busulfan

FLudarabine 150mg/m2 + Busulfan 12.8mg.kg

Trial Locations (9)

200025

RECRUITING

Ruijin Hospital, Shanghai

210029

RECRUITING

First Affiliated Hospital of Nanjin Medical Unviersity, Nanjin

215006

RECRUITING

First Affiliatied Hospital of Soochow University, Suzhou

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

361004

RECRUITING

Zhongshan Hospital, Xianmen University, Xiamen

530021

RECRUITING

923th Hospital PLA, Nanning

650000

RECRUITING

920th Hospital PLA, Kunming

Unknown

RECRUITING

Shanghai No10 Hospital, Shanghai

RECRUITING

Shanghai No 6 Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER